Renal dysfunction in cirrhosis

Purpose of review Renal dysfunction causes significant morbidity in cirrhotic patients. Diagnosis is challenging because it is based on serum creatinine, which is used to calculate estimated glomerular filtration rate, which itself is not an ideal measure of renal function in patients with cirrhosis. Finding the exact cause of renal injury in patients with cirrhosis remains problematic due to the limitations of the current diagnostic tests. The purpose of this review is to highlight studies used to diagnose renal dysfunction in patients with renal dysfunction and review current treatments. Recent findings New diagnostic criteria and classification of renal dysfunction, especially for acute kidney injury (AKI), have been proposed in hopes of optimizing treatment and improving outcomes. New biomarkers that help to differentiate structural from functional AKI in cirrhotic patients have been developed, but require further investigation. Vasoconstrictors are the most commonly recommended treatment of hepatorenal syndrome (HRS). Given the high mortality in patients with type 1 HRS, all patients with HRS should be evaluated for liver transplantation. When renal dysfunction is considered irreversible, combined liver–kidney transplantation is advised. Summary Development of new biomarkers to differentiate the different types of AKI in cirrhosis holds promise. Early intervention in cirrhotic patients with renal dysfunction offers the best hope of improving outcomes.

[1]  Constantine J Karvellas,et al.  Acute Kidney Injury in Cirrhosis. , 2015, Critical care clinics.

[2]  J. Huggins,et al.  Point-of-Care Echocardiography Improves Assessment of Volume Status in Cirrhosis and Hepatorenal Syndrome. , 2015, American Journal of the Medical Sciences.

[3]  D. Rockey,et al.  Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. , 2014, Journal of hepatology.

[4]  F. Carrilho,et al.  Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis , 2014, PloS one.

[5]  M. Perazella,et al.  Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury , 2014, Hepatology.

[6]  Paul L. Martin,et al.  Renal dysfunction in end-stage liver disease and post-liver transplant. , 2014, Clinics in liver disease.

[7]  F. Wong,et al.  Kidney damage biomarkers: Novel tools for the diagnostic assessment of acute kidney injury in cirrhosis , 2014, Hepatology.

[8]  D. Rockey To transfuse or not to transfuse in upper gastrointestinal hemorrhage? That is the question , 2014, Hepatology.

[9]  L. Magder,et al.  A Pilot Study to Evaluate Renal Hemodynamics in Cirrhosis by Simultaneous Glomerular Filtration Rate, Renal Plasma Flow, Renal Resistive Indices and Biomarkers Measurements , 2014, American Journal of Nephrology.

[10]  M. Poca,et al.  Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. , 2014, Journal of hepatology.

[11]  J. Dumortier,et al.  Creatinine‐ versus cystatine C‐based equations in assessing the renal function of candidates for liver transplantation with cirrhosis , 2014, Hepatology.

[12]  C. Parikh,et al.  Reconsidering a “chopped liver”: The need for improving glomular filtration rate estimation for hepatic transplantation , 2014, Hepatology.

[13]  R. Moreau,et al.  Glomerular filtration rate equations for liver‐kidney transplantation in patients with cirrhosis: Validation of current recommendations , 2014, Hepatology.

[14]  L. Magder,et al.  Performance of chronic kidney disease epidemiology collaboration creatinine‐cystatin C equation for estimating kidney function in cirrhosis , 2014, Hepatology.

[15]  P. Hayes,et al.  Review article: advances in the management of patients with cirrhosis and portal hypertension‐related renal dysfunction , 2014, Alimentary pharmacology & therapeutics.

[16]  C. Parikh,et al.  Acute kidney injury in patients with cirrhosis: perils and promise. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  M. Weir,et al.  Current Concepts in the Diagnosis and Classification of Renal Dysfunction in Cirrhosis , 2013, American Journal of Nephrology.

[18]  K. Moore Acute kidney injury in cirrhosis: A changing spectrum , 2013, Hepatology.

[19]  Johnny C. Hong,et al.  Simultaneous Liver–Kidney Transplantation Summit: Current State and Future Directions , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  R. Schrier,et al.  Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  F. Wong,et al.  Acute kidney injury in decompensated cirrhosis , 2012, Gut.

[22]  T. Nickolas,et al.  Urinary Neutrophil Gelatinase-Associated Lipocalin Predicts Mortality and Identifies Acute Kidney Injury in Cirrhosis , 2012, Digestive Diseases and Sciences.

[23]  D. Rockey,et al.  Acute Kidney Injury and Chronic Kidney Disease in Hospitalized Patients With Cirrhosis , 2011, Journal of Investigative Medicine.

[24]  K. Brown,et al.  Paneth cell‐derived interleukin‐17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury , 2011, Hepatology.

[25]  J. Dasta,et al.  Terlipressin in Hepatorenal Syndrome , 2011, The Annals of pharmacotherapy.

[26]  R. Bellomo,et al.  Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis , 2011, Gut.

[27]  S. Møller EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. , 2010, Journal of hepatology.

[28]  R. Moreau,et al.  The evaluation of renal function and disease in patients with cirrhosis. , 2010, Journal of hepatology.

[29]  R. Schrier,et al.  Renal failure in cirrhosis. , 2009, The New England journal of medicine.

[30]  N. Raina,et al.  Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment , 2009, Gut.

[31]  V. D’Agati,et al.  Acute kidney injury after hepatic ischemia and reperfusion injury in mice , 2008, Laboratory Investigation.

[32]  Vicente Arroyo,et al.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis , 2007, Postgraduate Medical Journal.

[33]  E. Esrailian,et al.  Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome , 2007, Digestive Diseases and Sciences.

[34]  W. Jiménez,et al.  Circulatory function and hepatorenal syndrome in cirrhosis , 2005, Hepatology.

[35]  G. Filler,et al.  Cystatin C as a marker of GFR--history, indications, and future research. , 2005, Clinical biochemistry.

[36]  F. Wong,et al.  Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome , 2004, Hepatology.

[37]  S. Nielsen,et al.  Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis , 2003, Gut.

[38]  D. Fish,et al.  Assessing renal function in cirrhotic patients: problems and pitfalls. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  V. Arroyo,et al.  Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. , 2003, Journal of hepatology.

[40]  F. Roudot-thoraval,et al.  Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study , 2002, Hepatology.

[41]  H. Schild,et al.  Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study , 2000, Gut.

[42]  T. Risler,et al.  Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[43]  P. Angeli,et al.  Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide , 1999, Hepatology.

[44]  Rosa Gilabert,et al.  Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems , 1998, Hepatology.

[45]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[46]  D. Schuppan,et al.  Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. , 1995, Renal failure.

[47]  P. Angeli,et al.  Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. , 1994, Archives of internal medicine.

[48]  I. Osberg,et al.  Bilirubin interference with the kinetic Jaffé method for serum creatinine. , 1978, Clinical chemistry.

[49]  E. Haber,et al.  Characterization of the renin-aldosterone system in decompensated cirrhosis. , 1977, Circulation research.